Growth inhibitory efficacy of Cornus officinalis in a cell culture model for triple‑negative breast cancer

  • Authors:
    • Nitin T. Telang
    • Hareesh B. Nair
    • George Y.C. Wong
  • View Affiliations

  • Published online on: March 21, 2019     https://doi.org/10.3892/ol.2019.10182
  • Pages: 5261-5266
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Triple‑negative breast cancer (TNBC) lacks the expressions of estrogen receptor‑α, progesterone receptor and human epidermal growth factor receptor‑2. The treatment options for TNBC include anthracyclin/taxol based conventional chemotherapy and small molecular inhibitor based targeted therapy. However, the therapeutic efficacy is limited by systemic toxicity and acquired tumor resistance; identification of less toxic testable alternatives is urgently required. Non‑toxic nutritional herbs are commonly used in traditional Chinese herbal medicine for general health management and may additionally represent a testable therapeutic alternative for TNBC. The present study examined the growth inhibitory efficacy of the nutritional herb Cornus officinalis (CO) in MDA‑MB‑231 cells, which represent a cell culture model for TNBC, and identified potential mechanistic leads. In MDA‑MB‑231 cells, CO induced dose‑dependent cytostatic growth arrest [inhibitory concentration (IC)50, 0.1% and IC90, 0.5%], and inhibited anchorage independent colony formation. Mechanistically, CO inhibited G1 to S phase transition leading to G1 arrest and decreased the expression of cyclin D1 and phosphorylated‑retinoblastoma proteins. CO additionally altered apoptosis specific BCL‑2 associated X protein/B‑cell lymphoma‑2 expression and upregulated pro‑apoptotic caspase‑3/7 activity. Collectively, these data provided mechanistic evidence for the efficacy of CO, and validated a mechanism‑based approach to prioritize efficacious nutritional herbs as testable alternatives for secondary prevention/treatment of TNBC.

References

1 

American Cancer Society, . Facts & Figures. American Cancer Society Inc. Atlanta, GA: 2017.

2 

Sørlie T, Perou CM, Tibshirany R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI

3 

Baselga J and Swain SM: Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 9:463–475. 2009. View Article : Google Scholar : PubMed/NCBI

4 

Dinh P, Satirou C and Piccart MJ: The evaluation of treatment strategies: Aiming at the target. Breast. 16 (Suppl 2):S10–S16. 2007. View Article : Google Scholar : PubMed/NCBI

5 

Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Siedge GW and Carey LA: Poly(ADP-ribose) polymerase inhibition: ‘Targeted’ therapy for triple-negative breast cancer. Clin Cancer Res. 16:4702–4710. 2010. View Article : Google Scholar : PubMed/NCBI

6 

Dean M, Fojo T and Bates S: Tumor stem cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005. View Article : Google Scholar : PubMed/NCBI

7 

Tindle HA, Davis RB, Phillips RS and Eisenburg DM: Trends in the use of complementary and alternative medicine by US adults: 1997–2002. Altern Ther Health Med. 11:42–49. 2005.PubMed/NCBI

8 

Molassiotis A, Scott JA, Kearney N, Pud D, Magri M, Selvekerova S, Bruyns I, Fernadez-Ortega P, Panteli V, Margulies A, et al: Complementary and alternative medicine use in breast cancer patients in Europe. Support Care Cancer. 14:260–267. 2006. View Article : Google Scholar : PubMed/NCBI

9 

Helyer LK, Chin S, Chui BK, Fitzgerald B, Verma S, Rakovitch E, Dranitsaris G and Clemons M: The use of complementary and alternative medicines among patients with locally advanced breast cancer - a descriptive study. BMC Cancer. 6:39–46. 2006. View Article : Google Scholar : PubMed/NCBI

10 

Mukherjee B, Telang N and Wong GY: Growth inhibition of estrogen receptor positive human breast cancer cells by Taheebo from the inner bark of Tabebuia avellanedae tree. Int J Mol Med. 24:253–260. 2009.PubMed/NCBI

11 

Li G, Sepkovic DW, Bradlow HL, Telang NT and Wong GY: Lycium barbarum inhibits growth of estrogen receptor positive human breast cancer cells by favorably altering estradiol metabolism. Nutr Cancer. 61:408–414. 2009. View Article : Google Scholar : PubMed/NCBI

12 

Telang NT, Li G, Sepkovic DW, Bradlow HL and Wong GY: Anti-proliferative effects of Chinese herb Cornus officinalis in a cell culture model for estrogen receptor-positive clinical breast cancer. Mol Med Rep. 5:22–28. 2012.PubMed/NCBI

13 

Telang N, Li G, Sepkovic D, Bradlow HL and Wong GY: Comparative efficacy of extracts from Lycium barbarum bark and fruit on estrogen receptor positive human mammary carcinoma MCF-7 cells. Nutr Cancer. 66:278–284. 2014. View Article : Google Scholar : PubMed/NCBI

14 

Telang N, Li G, Katdare M, Sepkovic D, Bradlow L and Wong G: Inhibitory effects of Chinese nutritional herbs in isogenic breast carcinoma cells with modulated estrogen receptor function. Oncol Lett. 12:3949–3957. 2016. View Article : Google Scholar : PubMed/NCBI

15 

Telang NT, Nair HB and Wong GY: Efficacy of Tabebuia avellanedae extract on a cell culture model for triple negative breast cancer. Cancer Res. 74 Suppl:SABCS, P5-14-02. 2014.

16 

Telang N, Nair HB and Wong GY: Effect of Cornus officinalis (CO) on a model for triple negative breast cancer. Cancer Res. 75 Suppl:SABCS, P3-09-04. 2015.

17 

Telang N, Nair HB and Wong GY: Efficacy of Dipsacus asperoides (DA) in a model for triple negative breast cancer. Cancer Res. 77 (Suppl 4):P4-13-04-P4-13-04. 2017. View Article : Google Scholar

18 

Seeram NP, Schutzki R, Chandra A and Nair MG: Characterization, quantification, and bioactivities of anthocyanins in Cornus species. J Agric Food Chem. 50:2519–2523. 2002. View Article : Google Scholar : PubMed/NCBI

19 

Chang JS, Chiang LC, Hsu FF and Lin CC: Chemoprevention against hepatocellular carcinoma by Cornus officinalis in vitro. Am J Chin Med. 32:717–725. 2004. View Article : Google Scholar : PubMed/NCBI

20 

Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 10:515–527. 2006. View Article : Google Scholar : PubMed/NCBI

21 

Subik K, Lee JF, Baxter L, Strzepak T, Costello D, Crowley P, Xing L, Hung MC, Bonfiglio T, Hicks DG and Tang P: The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer (Auckl). 4:35–41. 2010.PubMed/NCBI

22 

Hudis CA and Gianni L: Triple-negative breast cancer: An unmet medical need. Oncologist. 16 (Suppl 1):S1–S11. 2011. View Article : Google Scholar

23 

Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winer EP and Weeks JC: Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 118:5463–5472. 2012. View Article : Google Scholar : PubMed/NCBI

24 

Telang N: Putative cancer-initiating stem cells in cell culture models for molecular subtypes of clinical breast cancer. Oncol Lett. 10:3840–3846. 2015. View Article : Google Scholar : PubMed/NCBI

25 

Cox LA, Chen G and Lee EY: Tumor suppressor genes and their role in breast cancer. Breast Cancer Res Treat. 32:19–38. 1994. View Article : Google Scholar : PubMed/NCBI

26 

Burkhart DL and Sage J: Cellular mechanisms of tumor suppression by the retinoblastoma gene. Nat Rev Cancer. 8:671–682. 2008. View Article : Google Scholar : PubMed/NCBI

27 

Bosco EE and Knudson ES: RB in breast cancer: At the crossroads of tumorigenesis and treatment. Cell Cycle. 6:667–671. 2007. View Article : Google Scholar : PubMed/NCBI

28 

Sherr CJ and Roberts JM: CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI

29 

Musgrove EA, Caldon CE, Barraclough J, Stone A and Sutherland RL: Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 11:558–572. 2011. View Article : Google Scholar : PubMed/NCBI

30 

Alves CL, Elias D, Lyng M, Bak M, Kirkegaard T, Lykkesfeldt AE and Ditzel HJ: High CDK6 protects cells from fulvestrant-mediated apoptosis and is a predictor of resistance to fulvestrant in estrogen receptor-positive metastatic breast cancer. Clin Cancer Res. 22:5514–5526. 2016. View Article : Google Scholar : PubMed/NCBI

31 

VanArsdale T, Boshoff C, Arndt KT and Abraham RT: Molecular pathways: Targeting the cyclin D-CDK4/6 axis for cancer treatment. Clin Cancer Res. 21:2905–2910. 2015. View Article : Google Scholar : PubMed/NCBI

32 

Foidart P, Yip C, Radermacher J, Blacher S, Lienard M, Montero-Ruiz L, Maquoi E, Montaudon E, Château-Joubert S, Collignon J, et al: Expression of MT4-MMP, EGFR, and RB in triple-negative breast cancer strongly sensitizes tumors to erlotinib and palbociclib combination therapy. Clin Cancer Res. Nov 30–2018.(Epub ahead of print). doi: 10.1158/1078–0432.CCR-18-1880.

33 

Tait SW and Green DR: Mitochondrion and cell death: Outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 11:621–632. 2010. View Article : Google Scholar : PubMed/NCBI

34 

Ichim G and Tait SW: A fate worse than death: Apoptosis as an oncogenic process. Nat Rev Cancer. 16:539–548. 2016. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Telang, N.T., Nair, H.B., & Wong, G.Y. (2019). Growth inhibitory efficacy of Cornus officinalis in a cell culture model for triple‑negative breast cancer. Oncology Letters, 17, 5261-5266. https://doi.org/10.3892/ol.2019.10182
MLA
Telang, N. T., Nair, H. B., Wong, G. Y."Growth inhibitory efficacy of Cornus officinalis in a cell culture model for triple‑negative breast cancer". Oncology Letters 17.6 (2019): 5261-5266.
Chicago
Telang, N. T., Nair, H. B., Wong, G. Y."Growth inhibitory efficacy of Cornus officinalis in a cell culture model for triple‑negative breast cancer". Oncology Letters 17, no. 6 (2019): 5261-5266. https://doi.org/10.3892/ol.2019.10182